Defining How ADC Payloads Enhance Tumor Immunogenicity & Unlock Transformative Benefit With Immunotherapy

• Examining clinical ADC combinations with immunotherapy
• Differentiating ADC payloads by tumor-intrinsic immunogenic cell death (ICD) and activity on immune cells
• Assessing evidence of vedotin ADC immunogenicity in patients

Speakers:

Gregory Szeto

Scientific Director - ADC Discovery and Immunology

Pfizer